Sia Joseph, Tan Stephanie, Mohanakrishnan Narayan, Yu Kelvin, Ngan Samuel Y, Chander Sarat, Desai Jayesh, Lewin Jeremy, Hamilton Anne, Luen Stephen J, Gyorki David E, Snow Hayden, DiBella Claudia, O'Reilly-Harbidge Sarah, Orme Lisa M, Chu Julie, Bae Susie
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Cancer Med. 2025 May;14(10):e70973. doi: 10.1002/cam4.70973.
Desmoid tumors (DT) are rare, locally aggressive neoplasms that affect a young population and have a tendency for recurrence. There is sparse contemporary real-world data to guide practice for DT. Here, we report on a large cohort of DT patients, describing patterns of care and clinical outcomes.
Data on DT patients first seen between 2010 and 2021 were extracted from a prospective database and supplemented with a retrospective review of hospital records. Trends in treatment use were analyzed using the Cochran-Armitage test. Time-to-next intervention (TTNI) was estimated with the Kaplan-Meier method. Imaging response was categorized using the RECIST v1.1 criteria.
A total of 135 patients, 265 treatment episodes were analyzed. Median follow-up was 4.3 years. The common tumor sites were abdominal wall (27%), upper limb (20%), lower limb (16%), and intra-abdominal (15%). Over time, the proportion of patients receiving no upfront treatment was stable (2010-2013: 31%, 2014-2017: 35%, 2018-2021: 29%; p = 0.5), but there was increasing first-line use of NSAID/tamoxifen (7%, 41%, 47%; p < 0.001), and decreasing first-line use of radiotherapy (35%, 14%, 4%; p < 0.001) and surgery (28%, 8%, 18%; p < 0.05). At 5 years, the proportion not requiring treatment switch was highest following surgery (72%), radiotherapy (66%), and no upfront therapy (52%). 12% and 5% of patients without treatment achieved partial and complete imaging responses at 2 years.
We highlight the heterogeneity and trends in DT management over a 12-year period, affirming the role of active surveillance, radiotherapy, and surgery in selected patients. Medical therapies are evolving and may significantly influence the DT management paradigm.
韧带样瘤(DT)是一种罕见的、具有局部侵袭性的肿瘤,好发于年轻人群,且有复发倾向。目前缺乏当代真实世界的数据来指导DT的治疗实践。在此,我们报告了一大群DT患者,描述了其治疗模式和临床结局。
从一个前瞻性数据库中提取2010年至2021年间首次就诊的DT患者的数据,并对医院记录进行回顾性补充。使用 Cochr an-Armitage检验分析治疗使用趋势。采用Kaplan-Meier方法估计下次干预时间(TTNI)。使用RECIST v1.1标准对影像反应进行分类。
共分析了135例患者的265个治疗疗程。中位随访时间为4.3年。常见的肿瘤部位为腹壁(27%)、上肢(20%)、下肢(16%)和腹腔内(15%)。随着时间的推移,未接受初始治疗的患者比例保持稳定(2010 - 2013年:31%,2014 - 2017年:35%,2018 - 2021年:29%;p = 0.5),但非甾体抗炎药/他莫昔芬的一线使用增加(7%,41%,47%;p < 0.001),放疗(35%,14%,4%;p < 0.001)和手术(28%,8%,18%;p < 0.05)的一线使用减少。5年后,手术(72%)、放疗(66%)和未接受初始治疗(52%)后不需要更换治疗的患者比例最高。未接受治疗的患者中,12%和5%在2年时分别达到部分和完全影像缓解。
我们强调了12年间DT管理的异质性和趋势,肯定了主动监测、放疗和手术在特定患者中的作用。药物治疗正在不断发展,可能会显著影响DT的管理模式。